Zacks.com on MSN2h
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More
Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was ...
Hosted on MSN1d
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
Exelixis EXEL shares ended the last trading session 8.6% higher at $28.50. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...
GlobalData on MSN2d
Exelixis and MSD to trial cancer therapies together in clinical collaboration
US-based biotechnology companies Exelixis and MSD have partnered to assess the potential of combining their respective cancer ...
Zacks.com on MSN2d
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
Exelixis, Inc. EXEL entered into a clinical development collaboration agreement with pharma giant Merck MRK to advance the ...
FiercePharma1d
Exelixis stock rises as key drug Cabometyx withstands patent challenge
A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...
Exelixis: Navigating Patent Challenges and Future Growth Prospects with a Hold Rating
Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...
Hosted on MSN10d
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?
Shares of Exelixis, Inc. EXEL have risen 20.7% in the past three months compared with the industry’s growth of 6.3%. The ...